Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
24.9M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
2.15M
-
Shares change
-
+2.07M
-
Total reported value, excl. options
-
$4.09M
-
Value change
-
+$4.06M
-
Number of buys
-
47
-
Number of sells
-
-2
-
Price
-
$1.90
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q2 2025
51 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q2 2025.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.15M shares
of 24.9M outstanding shares and own 8.62% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (564K shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (233K shares), VANGUARD GROUP INC (232K shares), BlackRock, Inc. (179K shares), GSA CAPITAL PARTNERS LLP (133K shares), UBS Group AG (110K shares), JANE STREET GROUP, LLC (97.3K shares), BANK OF AMERICA CORP /DE/ (80.3K shares), OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) (80K shares), and MILLENNIUM MANAGEMENT LLC (78.1K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.